Faced with this unmet need, King’s researchers designed an undeniable and quick-to-produce kit called “Galliprost,” which improves the synthesis of radiotracers in PET images.
PET imaging relies on radiotracers such as gallium-68 to identify cancer cells. However, classical strategies for synthesizing gallium-68 radiotracers are complex and time-consuming.
The key to this lies in the engineering of chelating agents, which bind gallium-68 to a vector biomolecule.
A style suitable for design emerged from a framework of earlier paintings through Professor Robert Hider, Professor Emeritus of the School of Cancer and Pharmaceutical Sciences. Professor Hider analysed the progression of HOPOS hydroxypyridinonones as a remedy for β-thalassemia, a genetic disorder of the blood. . It affects 330,000 babies a year worldwide and young people with just one general red blood cell transfusion. However, those common transfusions lead to a poisonous accumulation of iron and without remedy to remove excess iron, patients die in the mid-twenties. Professor Hider designed in collaboration with Zhejiang University to produce the iron chelator hopo deferiprone, now a folk remedy for β-thalassemia with an average lifespan extension of forty-five years for the other 50,000 people treated each year.
Professor Hider’s HOPOs also presented a solution for radiotracers, based on the chemical similarities between iron and gallium: HOPOs were to bind to both gallium and iron. Hydroxypyridinone ligand) (THP) has been connected to PSMA, a molecule that binds to prostate cancer, for immediate and effective radiolabeling with gallium-68 of a prostate cancer imaging agent. Radiotagging can be conveniently done in five minutes instead of several hours. required for the above methods.
This formula makes it possible to produce the tracer on site, in a way adapted to frontline health personnel, without complex procedures or expensive infrastructures.
Then, a sterile kit, Galliprost, was designed to temporarily produce the marker under clinical conditions. The Galliprost marker was clinically assessed at King’s and its partner NHS Trust in over 1500 prostate cancer patients and appears to meet its key objectives of impacting patient control (around a third of patients replaced remedy resolution as a result of analysis) and synthesis was very fluid in a hospital setting.
The screening service was established in partnership with Guy and St Thomas Hospitals in 2017. More than 1000 patients have benefited from Guy and St Thomas hospitals alone. 1,500 in line with the patient.
King’s work has also led to international circulation. In 2019, Theragnostics partnered commercially with GE Healthcare to ensure Galliprost’s global distribution, readiness and further progress. Theragnostics reported data from a phase 2 clinical study that showed that one-third of patients with newly diagnosed prostate cancer, and more than 50% of patients with recurrent biochemical disease, had their treatment plans altered as a result of the GalliProst analysis. Replacement in patient control was greater than 75% in a post-radical radiation therapy setting.
Please indicate the appropriate maximum category to facilitate the processing of your application
Thank you for taking the time to provide your feedback to the editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.